Abstract 17690: Statin Use Protects Against Systemic Inflammation in a Geriatric Population: The Brazilian Study on Healthy Aging
BACKGROUND: Clinical trial data has demonstrated that statins reduce vascular inflammation. However, data describing the association between statin use and markers of vascular inflammation such as hs-CRP in people aged 80 years and older is very limited. In this study we assess the association between statin use and systemic inflammation in a healthy elderly population..
METHODS: We conducted a cross-sectional analysis of 208 elderly patients (85 ± 4 years, 21% males) . Demographic & anthropometric data including medication use was collected. Laboratory tests conducted include hsCRP. Serum hs-CRP levels>3mg/dL was considered to be elevated.
RESULTS: Overall, 39% of our population was on statins. The prevalence of statin use did not differ significantly across genders however statin users tended to be significantly younger than non-users (p=0.04). The prevalence of elevated hs-CRP was 33%. Hs-CRP was significantly lower among statin users compared to non-users (2.53 ± 4.37 vs. 4.72±7.98 p=0.026). Statin use was associated with a significantly reduced prevalence of elevated hs-CRP (Odds Ratio- 0.34 (0.18-0.66) (see table). The association remained significant even after adjusting for age, gender, cigarette smoking, serum lipids, diabetes, hypertension and physical activity.
CONCLUSION: Octogenarians and older individuals on statins had a 60-65% lower likelihood of elevated subclinical vascular inflammation as measured by hs-CRP levels. The current study demonstrates that the beneficial effect of statin therapy in reducing vascular inflammation may also extend to the very elderly population. There is an urgent need to assess if statin use in this elderly population may also result in reduced CVD events and provide mortality benefit.
- © 2013 by American Heart Association, Inc.